« Previous
Next »
Titles
- Associations between county-level vaccination rates and COVID-19 outcomes among Medicare beneficiaries2
- CMC postapproval manufacturing changes for specified biological products to be documented in annual reports2
- Comparing outcomes for dual eligible beneficiaries in integrated care: final report2
- Conduct of clinical trials of medical products during the COVID-19 public health emergency: guidance for industry, investigators, and institutional review boards2
- Health insurance coverage and access to care among Latinos: recent trends and key challenges2
- Policy for temporary compounding of certain alcohol-based hand sanitizer products during the public health emergency: immediately in effect guidance for industry2
- Submission of plans for cigarette packages and cigarette advertisements (revised)2
- Temporary policy for preparation of certain alcohol-based hand sanitizer products during the public health emergency (COVID-19)2
- A comparison of brand-name drug prices among selected federal programs1
- A public option for health insurance in the nongroup marketplaces: key design considerations and implications1
- ACF cannot ensure that all child victims of abuse and neglect have court representation1
- ANDAs for certain highly purified synthetic peptide drug products that refer to listed drugs of rDNA origin1
- Arthroscopy pump tubing sets intended for multiple patient use - Premarket Notification (510(k)) submissions: guidance for industry and Food and Drug Administration staff1
- Availability of supplemental benefits in Medicare Advantage plans in rural and urban areas1
- Awake fiber optic intubation1
- BPC’s key considerations for developing a Medicaid home and community-based services benefit1
- Behavioral health and COVID-19: higher-risk populations and related federal relief funding : report to congressional committees1
- Biomedical research: information on federal contributions to remdesivir : report to Congressional addressees1
- Bipartisan solutions to improve the availability of long-term care1
- Bispecific antibody development programs1